Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma

BACKGROUND: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and immune checkpoint inhibitors showed promising results for advanced hepatocellular carcinoma. Considering diffe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ther Adv Med Oncol
Hlavní autoři: He, Min-Ke, Liang, Run-Bin, Zhao, Yang, Xu, Yu-Jie, Chen, Huan-Wei, Zhou, Yuan-Min, Lai, Zhi-Cheng, Xu, Li, Wei, Wei, Zhang, Yao-Jun, Chen, Min-Shan, Guo, Rong-Ping, Li, Qi-Jiong, Shi, Ming
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2021
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8010824/
https://ncbi.nlm.nih.gov/pubmed/33854567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211002720
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky